<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555099</url>
  </required_header>
  <id_info>
    <org_study_id>D2340C00011</org_study_id>
    <secondary_id>2011-005389-39</secondary_id>
    <nct_id>NCT01555099</nct_id>
  </id_info>
  <brief_title>Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol</brief_title>
  <official_title>A Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group,Multi-centre Study to Assess the Efficacy and Safety of Two Staggered Dose Levels of Inhaled Once Daily AZD5423 or Twice Daily Budesonide for 12 Weeks in COPD Patients on a Background Therapy of Formoterol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of two staggered dose levels of&#xD;
      inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a&#xD;
      background therapy of formoterol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase-II, double-blind, placebo-controlled, randomised, parallel-group,multi-centre study&#xD;
      to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423&#xD;
      or twice daily budesonide for 12 weeks in COPD patients on a background therapy of&#xD;
      formoterol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline to mean of weeks 8 to 12 in pre-dose forced expiratory volume in 1 sec (FEV1)</measure>
    <time_frame>Baseline (week 0), and at week 8, 10, and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in twenty-four hour plasma cortisol</measure>
    <time_frame>Baseline (week 0), and at week 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first exacerbation (hospitalisation, oral/parenteral corticosteroid, oral/parenteral antibiotics)</measure>
    <time_frame>Baseline(week 0) and week 2, 4, 8, 10, 12 and daily by eDairy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change from baseline in pre-dose hsCRP at week 4 and 12</measure>
    <time_frame>Baseline(week 0), and at week 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of AZD5423 in terms of Cmax, tmax, AUC(0-24h), CL/F, Cav in subset of patients</measure>
    <time_frame>Week 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of St George's Respiratory Questionnaire (SGRQ-C) responders and Overall Score</measure>
    <time_frame>Baseline(week 0), and at week 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Baseline/Transitional Dyspnea Index (BDI/TDI) Score</measure>
    <time_frame>Baseline(week 0), and at week 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Breathlessness, Cough and Sputum Scale (BCSS) Score</measure>
    <time_frame>Daily by eDairy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline to mean of week 2 and 4 pre-dose forced expiratory volume in 1 sec (FEV1)</measure>
    <time_frame>Baseline (week 0), and at week 2 and 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in pre-dose FEV1</measure>
    <time_frame>Baseline (week 0) and at week 2, 4, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>AZD5423</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator to which the new study drug will be compared</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No drug to which both other arms will be compared</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5423</intervention_name>
    <description>oral inhaled</description>
    <arm_group_label>AZD5423</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>oral inhaled</description>
    <arm_group_label>Budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral inhaled</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent prior to conducting any study specific&#xD;
             procedures&#xD;
&#xD;
          -  Men or women aged ≥ 40 years&#xD;
&#xD;
          -  Men or post-menopausal or surgically sterile women. Women will be considered&#xD;
             post-menopausal if they have been amenorrheic for at least 12 months, and have a&#xD;
             follicle stimulating hormone (FSH) plasma concentration within the postmenopausal&#xD;
             range as defined by the laboratory. Male patients should be willing to use barrier&#xD;
             contraception, i.e. condom (with spermicide) from the day of dosing until at least 5&#xD;
             weeks after the last dose with the study drug.&#xD;
&#xD;
          -  Clinical diagnosis of COPD for more than 1 year at Visit 1, according to GOLD&#xD;
             guidelines&#xD;
&#xD;
          -  Current maintenance therapy with LABA and/or LAMA, ICS/LABA or ICS plus LAMA&#xD;
             combination&#xD;
&#xD;
          -  Current or ex-smokers with a smoking history equivalent to at least 10 pack years (1&#xD;
             pack year = 20 cigarettes smoked per day for one year)&#xD;
&#xD;
          -  Post-bronchodilator FEV1 ≥40 and ≤ 80% of the predicted normal value&#xD;
&#xD;
          -  Post-bronchodilator FEV1/FVC &lt;0,7&#xD;
&#xD;
          -  Reversibility of airway obstruction according to reversibility test performed at visit&#xD;
             2, defined as an increase in FEV1 of ≥10% relative baseline after inhalation of in&#xD;
             total 400 μg salbutamol or 1 mg terbutaline sulphate&#xD;
&#xD;
          -  Chest radiography (not older than 12 months at Visit 2) not showing any pathological&#xD;
             changes that would make the patient unsuitable for inclusion as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Able to read and write and use the electronic devices (eDiary and electronic&#xD;
             spirometry)&#xD;
&#xD;
          -  Ability to complete an eDiary correctly. Baseline diary data had to be recorded for at&#xD;
             least 8 (any 8) of the last 10 days of the run-in period to accept patients for&#xD;
             randomized treatment (Randomisation Criteria at Visit 3).&#xD;
&#xD;
          -  Provision of informed consent for genetic sampling and analyses. If a patient declines&#xD;
             to participate in the pharmacogenetic research, there will be no consequence or loss&#xD;
             of benefit to the patient. The patient will not be excluded from other aspects of the&#xD;
             study described in the Clinical Study Protocol (CSP), as long as they consent&#xD;
             (Inclusion criteria for patients taking part in the pharmacogenetic research)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant disease or disorder (eg, cardiovascular, pulmonary other than COPD,&#xD;
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,&#xD;
             malignant, psychiatric, major physical impairment) which, in the opinion of the&#xD;
             investigator, may either put the patient at risk because of participation in the&#xD;
             study, or influence the results of the study, or the patient's ability to participate&#xD;
             in the study&#xD;
&#xD;
          -  Any clinically relevant abnormal findings in clinical chemistry, haematology,&#xD;
             urinalysis, physical examination, pulse, blood pressure or ECG at Visit 2, which, in&#xD;
             the opinion of the investigator, may put the patient at risk because of his/her&#xD;
             participation in the study&#xD;
&#xD;
          -  Requirement for long term oxygen therapy&#xD;
&#xD;
          -  An exacerbation of COPD, defined as use of oral or parenteral glucocorticosteroids or&#xD;
             oral/parenteral antibiotics or hospitalisation related to COPD within 6 weeks of Visit&#xD;
             2&#xD;
&#xD;
          -  Participation in or scheduled for an intensive COPD rehabilitation program&#xD;
&#xD;
          -  Known or suspected hypersensitivity to study therapy or excipients of the study drug&#xD;
&#xD;
          -  History of current alcohol or drug abuse or any condition associated with poor&#xD;
             compliance as judged by the investigator&#xD;
&#xD;
          -  Plasma donation within one month of screening or any blood donation/blood loss &gt;500 mL&#xD;
             during the 3 months prior to screening.&#xD;
&#xD;
          -  Participation in any clinical study with an investigational drug or new formulation of&#xD;
             a marketed drug in the 3 months prior to Visit 2&#xD;
&#xD;
          -  Planned in-patient surgery or hospitalisation during the study&#xD;
&#xD;
          -  Previous randomisation of treatment into the present study&#xD;
&#xD;
          -  Involvement in the planning and conduct of the study (applies to both AstraZeneca&#xD;
             staff or staff at the study site)&#xD;
&#xD;
          -  Previous allogeneic bone marrow transplant (Exclusion criteria for patients taking&#xD;
             part in the pharmacogenetic research)&#xD;
&#xD;
          -  Non-leukocyte depleted whole blood transfusion within 120 days of the date of the&#xD;
             genetic sample collection (Exclusion criteria for patients taking part in the&#xD;
             pharmacogenetic research)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego w Łodzi, ul. Kopcińskiego 22, 90-153, Łódź, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doganovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille Cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice Cedex 01</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorzow Wlkp</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Humenne</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, FEV1, AZD5423</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 19, 2015</submitted>
    <returned>January 29, 2015</returned>
    <submitted>March 31, 2015</submitted>
    <returned>April 14, 2015</returned>
    <submitted>July 29, 2019</submitted>
    <returned>September 6, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

